Compare MEI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | CCCC |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 404.7M |
| IPO Year | 1994 | 2020 |
| Metric | MEI | CCCC |
|---|---|---|
| Price | $13.40 | $4.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $9.00 | ★ $12.20 |
| AVG Volume (30 Days) | 580.8K | ★ 2.4M |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 49.14 | 16.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,300,000.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.24 | 1.02 |
| 52 Week Low | $4.88 | $1.40 |
| 52 Week High | $15.55 | $4.60 |
| Indicator | MEI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 62.78 | 62.91 |
| Support Level | $6.72 | $2.10 |
| Resistance Level | $13.53 | $4.60 |
| Average True Range (ATR) | 0.97 | 0.37 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 73.21 | 77.88 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.